Navigation Links
FDA's New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
Date:8/24/2010

WALTHAM, Mass., Aug. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing medications. Most notably, the FDA controls state that LABA/ICS combination medications should be reserved for patients who remain uncontrolled despite treatment with controller medications (e.g., single-agent ICS therapies).

According to the new report entitled Treatment Algorithms in Asthma, more than 40 percent of surveyed physicians report that they will decrease their prescribing of LABA/ICS combinations prior to attempting treatment with a single-agent ICS drug over the next 12 months.

While surveyed physicians indicate that the FDA controls for LABA-containing drugs will affect their decision to prescribe a LABA/ICS combination therapy prior to attempting treatment with a single-agent ICS, surveyed physicians also report that first-line prescribing of LABA/ICS combinations remains common. In particular, surveyed physicians are most likely to prescribe a LABA/ICS combination, such as GlaxoSmithKline's Advair or AstraZeneca's Symbicort, as a first-line maintenance therapy for newly diagnosed adult patients with moderate or severe persistent asthma.

"Some surveyed physicians say they will decrease their use of LABA/ICS combination medications for the treatment of asthma, a trend that may have positive implications for the single-agent ICS class of therapies," said Decision Resources Analyst Martin Quinn. "As a result, marketers of LABA/ICS combination medications and single-agent ICS therapies must focus not only on competitive dyna
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... in Combination with Chemotherapy, FREMONT, Calif. ... pharmaceutical company discovering and developing novel,RNA interference ... Research published results on efficacy of siRNA ... lung cancer (NSCLC) in,the edition dated October ...
... Pivotal Data Show Prophylaxis Treatment with Kogenate FS ... in Children with No Pre-Existing,Joint Damage, BERKELEY, ... that the U.S. Food and Drug Administration (FDA) ... to reduce the frequency of bleeding episodes and ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Hospital's Karmanos Center for Natural Birth . The Karmanos Center for ... safe natural childbirth experience. With nurses and caregivers that are trained in holistic ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers ... Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. Timber frame ... important day for the entire community as the culmination of months of effort, planning, ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled ... talked about a woman’s unfortunate experience having cosmetic skin procedures done by a ... resulted in blistering, swelling, bruising, and pain. This woman’s experience is only one ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone ... in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status ... entry was made recording the minutes of the status conference, which was held that ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... Joins Thousands of Participants in Inspirational Closing Ceremony; ... Breast Cancer Organizations, WASHINGTON, May 4 ... Reese Witherspoon was a special guest at the,sixth ... this weekend,cheering on and joining walkers on their ...
... to an expanding waist line, weight gain and a tendency ... of a study published today in the journal Nature Genetics. ... is significantly more common in those with Indian Asian than ... Heart Foundation, could lead to better ways of treating obesity. ...
... knowledge gap, experts say , , SUNDAY, May 4 (HealthDay ... surprisingly low knowledge of child development, including basic concepts ... should act, a new study finds. , For instance, ... 1-year-olds can,t tell the difference between right and wrong, ...
... Study shows only 49% intended to do so if child ... News) -- New research shows that only half of American ... papillomavirus (HPV) if the girls are under the age of ... which is sexually transmitted, is the primary cause of cervical ...
... assumptions, children are more vulnerable to the harmful effects ... they are in early childhood, according to a Cincinnati ... 4 at the annual meeting of the Pediatric Academic ... protecting toddlers from lead exposure, our study shows that ...
... U.S. parents have a surprisingly low-level knowledge of ... childs physical, social and emotional growth, according research ... which suggest that such false parenting assumptions can ... kids of much-needed cognitive stimulation, will be presented ...
Cached Medicine News:Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Gene sequence that can make half of us fatter is discovered 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 2Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 3Health News:Children more vulnerable to harmful effects of lead 2Health News:Nearly one-third of US parents don't know what to expect of infants 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Manual Table For Slit Lamp...
Medicine Products: